The utility of dobutamine stress echocardiography for the diagnosis of coronary artery disease in the HIV population

Echocardiography

Volumn 27, Issue 10, 2010, Pages 1228-1232

  Lytwyn, Matthew ^a   Fallah Rad, Nazanin ^a   Walker, Jonathan ^a   Bohonis, Sheena ^a   Hussain, Farrukh ^b   Barac, Ivan ^b   Jassal, Davinder S ^a,b,c  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

^b Section of Cardiology   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

coronary angiography; human immunodeficiency virus; stress echocardiography

Indexed keywords

DOBUTAMINE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG DOSE ESCALATION; FEMALE; HEART CATHETERIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STRESS ECHOCARDIOGRAPHY;

CARDIOTONIC AGENTS; CORONARY ARTERY DISEASE; DOBUTAMINE; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 78649755220     PISSN: 07422822     EISSN: 15408175     Source Type: Journal    
DOI: 10.1111/j.1540-8175.2010.01218.x     Document Type: Article

References (45)

1. University of California: HIV InSite: North America, September 2008. Available from. page=cr07. Accessed Dec 26, 2009.
2. Egger M, May M, Chêne G, et al,: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360 (9327): 119-129. (Pubitemid 34786200)
3. McDonald CL, Kaltman JR,: Cardiovascular disease in adult and pediatric HIV/AIDS. J Am Coll Cardiol 2009; 54 (13): 1185-1188.
4. Currier JS,: Update on cardiovascular complications in HIV infection. Top HIV Med 2009; 3: 98-103.
5. Ho JE, Hsue PY,: Cardiovascular manifestations of HIV infection. Heart 2009; 95 (14): 1193-1202.
6. Jevtovic D, Dragovic G, Salemovie D, et al,: The metabolic syndrome, an epidemic among HIV-infected patients on HAART. Biomed Pharmacother 2009; 63 (5): 337-342.
7. Barbaro G, Iacobellis G,: Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009; 9 (1): 37-42.
8. Kingsley LA, Cuervo-Rojas J, Munoz A, et al,: Subclinical coronary atherosclerosis HIV infection and antiretroviral therapy: Multicenter AIDS cohort study. AIDS 2008; 22 (13): 1589-1599.
9. Panos G, Samonis G, Alexiou VG, et al,: Mortality and morbidity of HIV infected patients receiving HAART: A cohort study. Curr HIV Res 2008; 6 (3): 257-260.
10. Passalaris JD, Sepkowitz KA, Glesby MJ,: Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000; 31 (3): 787-797.
11. Boccara F,: Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: Type, incidence and associated risk factors. AIDS 2008; 22: S19-26.
12. Lo J, Grinspoon S,: Cardiovascular disease in HIV-infected patients: Does HIV infection in and of itself increase cardiovascular risk? Curr Opin HIV AIDS 2008; 3 (3): 207-213.
13. Douglas PS, Khandheria B, Stainback RF, et al,: ACCF/ASE/ACEP/AHA/ASNC/ SCAI/SCCT/SCMR 2008 appropriateness criteria for stress echocardiography: A report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, American Society of Echocardiography, American College of Emergency Physicians, American Heart Association, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance endorsed by the Heart Rhythm Society and the Society of Critical Care Medicine. J Am Coll Cardiol 2008; 51 (11): 1127-1147.
14. Pellikka PA, Nagueh SF, Elhendy AA, et al,: American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007; 20 (9): 1021-1041.
15. Sicari R, Nihoyannopoulos P, Evangelista A, et al,: Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr 2008; 9 (4): 415-437.
16. Baptista J, Arnese M, Roelandt JR, et al,: Quantitative coronary angiography in the estimation of the functional significance of coronary stenosis: Correlations with dobutamine-atropine stress test. J Am Coll Cardiol 1994; 23 (6): 1434-1439.
17. Fleiss JL,: Statistical Methods for Rates and Proportions. 2nd Ed. New York: Wesley and Sons, 1981; 217-225.
18. Eugenin EA, Morgello S, Klotman ME, et al,: Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: Implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol 2008; 172 (4): 1100-1111.
19. Libby P,: Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
20. Ross R,: Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
21. Mehta NJ, Khan IA,: HIV-associated coronary artery disease. Angiology 2003; 54 (3): 269-275.
22. Lewis W,: Atherosclerosis in AIDS: Potential pathogenetic roles of antiretroviral therapy and HIV. J Mol Cell Cardiol 2000; 32 (12): 2115-2129.
23. Holmberg SD, Moorman AC, Williamson JM, et al,: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360 (9347): 1747-1748.
24. Holmberg SD, Moorman AC, Greenberg AE,: Trends in rates of myocardial infarction among patients with HIV. N Engl J Med 2003; 349 (21): 1993-2003.
25. Barbaro G, Di Lorenzo G, Cirelli A, et al,: An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 2003; 25 (9): 2405-2418.
26. Moller N, Sabin CA, Monforte A, et al,: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
27. Hsue PY, Lo JC, Franklin A, et al,: rogression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109 (13): 1603-1608.
28. Stein JH, Klein MA, Bellehumeur JL, et al,: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104 (3): 257-262.
29. Van Wijk JP, De Koning EJ, Cabezas MC, et al,: Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006; 47 (6): 1117-1123.
30. Mary-Krause M, Cotte L, Simon A, et al,: Increased risk of myocardial infarction with the duration of protease inhibitor therapy in HIV-infected me. AIDS 2003; 17 (17); 2529-2531.
31. Micheletti RG, Fishbein GA, Fishbein MC, et al,: Coronary atherosclerotic lesions in human immunodeficiency virus-infected patients: A histopathologic study. J Carpath 2009; 18: 28-36.
32. Schmermund A, Schwartz RS, Adamzik M, et al,: Coronary atherosclerosis in unheralded sudden coronary death under age 50: Histo-pathologic comparison with 'healthy' subjects dying out of hospital. Atherosclerosis 2001; 155 (2): 499-508.
33. Fishbein MC, and, Siegel RJ,: How big are atherosclerotic plaques that rupture. Circulation 1996; 94 (10); 2662-2666.
34. Davis MJ,: Stability and instability: Two faces of coronary atherosclerosis. Circulation 1996; 94: 2013-2020.
35. Davis MJ, Richardson PD, Woolf N, et al,: Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-381.
36. Fleischmann KE, Hunink MG, Kuntz KM, et al,: Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998; 280 (10): 913-920.
37. Quinones M, Verani MS, Haichin RM, et al,: Exercise echocardiography versus thallium-201 single photon emission computed tomography on the evaluation of coronary artery disease: Analysis of 292 patients. Circulation 1992; 85: 1217-1218.
38. Bax JJ, Geleijnse ML, Boersma E, et al,: Noninvasive evaluation of ischaemic heart disease: Myocardial perfusion imaging or stress echocardiography? Eur Heart J 2003; 24 (9): 789-800.
39. Smart SC, Bhatia A, Hellman R, et al,: Dobutamine-atropine stress echocardiography and dipyridamole sestamibi scintigraphy for the detection of coronary artery disease: Limitations and concordance. J Am Coll Cardiol 2000; 36 (4): 1265-1273.
40. Marwick T, D'Hondt AM, Baudhuin T, et al,: Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: Combination with echocardiography or scintigraphy, or both? J Am Coll Cardiol 1993; 22 (1): 159-167.
41. Armstrong WF, Zoghbi WA,: Stress echocardiography: Current methodology and clinical applications. J Am Coll Cardiol 2005; 45 (11): 1739-1747.
42. Ryan T, Segar DS, Sawada SG, et al,: Detection of coronary artery disease with upright bicycle exercise echocardiography. J Am Soc Echocardiogr 1993; 6 (2): 186-197.
43. McNeil AJ, Fioretti PM, El-Said SM, et al,: Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. Am J Cardiol 1992; 70 (1): 41-46.
44. Cohen JL, Greene TO, Ottenweller J, et al,: Dobutamine digital echocardiography for detecting coronary artery disease. Am J Cardiol 1991; 67 (16): 1311-1318.
45. Innocenti F, Caldi F, Tassinari I, et al,: Prognostic value of exercise stress test and dobutamine stress echocardiography in patients with known coronary artery disease. Echocardiography 2009; 26: 1-9.